Nanomedicine Market (By Modality: Treatments, Diagnostics; By Application: Drug Delivery, Diagnostic Imaging, Vaccines, Regenerative Medicine, Implants, Others; By Nanomolecule Type: Nanoparticles, Nanoshells, Nanotubes, Nanodevices; By Indication: Oncological Diseases, Infectious Diseases, Cardiovascular Diseases, Others) - Global Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023 – 2032


The global nanomedicine market size was estimated at US$ 170 billion in 2022 and it is expected to hit over US$ 493.67 billion by 2032 with a registered CAGR of 11.30% from 2023 to 2032.

Nanomedicine Market Size, Statistics 2023 to 2032

Access our Healthcare Data Intelligence Tool with 10000+ Database, Visit: Towards Healthcare


Nanomedicine Market  in U.S. 2023 To 2032

The U.S. nanomedicine market size was valued at US$ 58.31 billion in 2022 and it is predicted to be worth around US$ 170.86 billion by 2032 with a registered CAGR of 11.40% between 2023 to 2032.

U. S. Nanomedicine Market  Size 2023 To 2032

North America dominated the nanomedicine market in 2022. The technological advancements combined with relevant applications in early disease diagnosis, prevention, and prophylactic of acute and chronic disorders are expected to drive the nanomedicine market growth in the U.S.

Nanomedicine Market Share, By Region, 2022 (%)

Asia-Pacific, on the other hand, is expected to develop at the fastest rate during the forecast period. Various research and development efforts are also now occurring in the region on pharmaceuticals and diagnostics based on nanotechnology, which may fuel the nanomedicine market expansion.   

Growth Factors

The nanomedicine is the use of nanotechnology to accomplish healthcare innovation. It makes use of the properties created by a material at its nanometric scale of 10-9 m, which often differ from the same substance at a larger size in terms of physics, chemistry, and biology. Furthermore, the nanometric scale of many biological procedures in the human body, allowing nanomaterials and nanoparticles to potentially cross natural barriers to reach new delivery sites and interact with DNA or small proteins at various levels, whether in blood or within organs, cells, and tissues.

Nanomedicine offers the potential to improve early detection and prevention as well as diagnosis, therapy, and follow up for a wide range of disorders including cancer. In total, hundreds of nanomedicine products are currently undergoing clinical trials, spanning all main disorders such as cardiovascular, neurological, inflammatory, and musculoskeletal. Nanomedicine is an enabling technology in all fields of healthcare with over 80 marketed products ranging from nano-delivery and pharmaceuticals to medical imaging, biomaterials, and diagnostics.

Emerging methods for drug delivery, increased use of nanomedicine across various applications, increased government backing and funding, the surge in demand for therapies with fewer side effects, and cost effectiveness of therapies are driving the worldwide nanomedicine market. On the other hand, the nanomedicine market’s growth is limited by the lengthy licensing process and the hazards involved with nanomedicine. Furthermore, the surge in nanodrug out licensing and the expansion of healthcare facilities in emerging nations are expected to give several chances for the nanomedicine market to flourish.

Report Scope of the Nanomedicine Market

Report Coverage Details
Market Size by 2032 USD 493.67 Billion
Growth Rate from 2023 to 2032

CAGR of 11.30%

Largest Market North America
Fastest Growing Market Asia Pacific
Base Year 2022
Forecast Period 2023 to 2032
Segments Covered Modality, Application, Indication, Nanomolecule Type, Geography
Companies Mentioned Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services Inc., Luminex Corporation, Merck & Company Inc., Nanosphere Inc.

 

The use of nanotechnology-based contrast reagents for diagnosis and monitoring of pharmacological effects on an unprecedentedly short timescale is also expected to fuel future growth. The demand is also expected to be influenced by the demand for biodegradable implants with extended lifespans that allow for tissue repair. Nano formulations with triggered release for tailored pharmacokinetics, nano-substances for the tumor management coupled with the radiation and nanoparticles that functions for targeted in-vivo stimulation of the cell production are expected to drive research and development in the future years. 

The rising out licensing of nano medicines and the expansion of healthcare facilities in emerging markets are helping to create a market growth potential. The technological improvements such as applications in early illness diagnosis, prevention of acute and chronic ailments, and preventive intervention are likely to drive the nanomedicine market expansion. The nanotechnology entails a number of steps. The nanotechnology is the miniaturization of bigger structures and molecules on a nanometric scale, which has influenced the technology’s adoption.

The worldwide nanomedicine market is likely to be driven by the increasing applications of nanomedicine as a result of technological developments in nanotechnology. There has been a boom in research activity in the field of nanotechnology, both by governments and private institutions as well as in the experimental use of this technology to cure a number of chronic diseases. This, together with the nanomedicine market’s high unsatisfied medical needs, large geriatric population, and rising incidence of chronic and acute disorders is expected to give it a major boost to the nanomedicine market.

The increased global burden of chronic and infectious disorders is driving the global nanomedicine market. Cancer is the second largest cause of death worldwide, according to the World Health Organization, responsible for more than 9.5 million deaths in 2018. The nanomedicine’s ability to control lymphoid and myeloid cell activity as well as improve anticancer immunity and immunotherapy efficacy will boost its use in cancer treatment. Furthermore, the opening of a NanoTherm treatment facility is likely to help the business to flourish.

Thus, the rising prevalence of genetic and cardiovascular illnesses, increasing breakthroughs in nanoscale technologies for diagnostic processes and a growing preference for tailored treatments are all driving the growth of the healthcare nanotechnology industry. On the other hand, the nanomedicine market’s expansion is hampered by severe regulatory issues and the high cost of nanoparticle assisted medicine in comparison to its traditional counterparts.   

Application Insights

In 2022, the regenerative medicine segment dominated the nanomedicine market. The regenerative medicine is a new field of medicine that aims to restore of restore normal function by replacing, engineering, or regenerating human cells, tissues, and organs that have been lost or harmed due to age, diseases, or congenital abnormalities.

The diagnostic imaging segment, on the other hand, is predicted to develop at the quickest rate in the future years. The diagnostic imaging refers to a variety of procedures for looking into the body to determine the source of an illness and damage and confirm a diagnosis. Doctors also use it to assess how well a patient’s body responds to fracture or diseases therapy.   

Indication Insights

In 2022, the cardiovascular diseases segment dominated the nanomedicine market. The heart or blood vessels are affected by this sort of sickness. High blood pressure, smoking, high cholesterol, a poor diet, and obesity can all raise the risk of cardiovascular disease.

The oncological diseases segment, on the other hand, is predicted to develop at the quickest rate in the future years. The main oncological disease is cancer. The different types of cancers such as breast cancer, stomach cancer, and lung cancer are categorized into oncological diseases.

Key Developments

  • NaNotics LLC and Mayo Clinics announced a research partnership in January 2022 to develop a NaNot that targets the soluble form of PD-L1, a tumor generated immune inhibitor.
  • In March 2021, an agreement between Barcelona institutions and the University of Manchester’s Nanomedicine Lab was awarded EUR 12 million in funding to boost the European medical nanotechnology industry.
  • Medtronic PLC introduced its new Adaptix Interbody System, a guided titanium spinal implant with Titan nanoLOCK Surface Technology, in October 2020.
  • Ablynx and Novo Nordisk announced a global collaboration and licensing agreement in November 2015 to develop and discover novel pharmaceuticals using multi-specific nanobodies. This strategic alliance is expected to increase product net annual sales, boosting the nanomedicine market growth.  

Some of the prominent players in the global nanomedicine market include:

  • Sanofi SA
  • Abbott
  • Pfizer Inc.
  • CombiMatrix Corporation
  • GE Healthcare
  • Celgene Corporation
  • Johnson & Johnson Services Inc.
  • Luminex Corporation
  • Merck & Company Inc.
  • Nanosphere Inc.  

Segments Covered in the Report

(Note*: We offer report based on sub segments as well. Kindly, let us know if you are interested)

By Modality

  • Treatments
  • Diagnostics

By Application

  • Drug Delivery
  • Diagnostic Imaging
  • Vaccines
  • Regenerative Medicine
  • Implants
  • Others 

By Indication

  • Oncological Diseases
  • Infectious Diseases
  • Cardiovascular Diseases
  • Orthopedic Diseases
  • Neurological Diseases
  • Urological Diseases
  • Ophthalmological Diseases
  • Immunological Diseases
  • Others

By Nanomolecule Type

  • Nanoparticles
    • Metal & Metal Oxide Nanoparticles
    • Liposomes
    • Polymers & polymer drug conjugates
    • Hydrogel nanoparticles
    • Dendrimers
    • Inorganic nanoparticles
  • Nanoshells
  • Nanotubes
  • Nanodevices

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • France
  • Asia-Pacific
    • China
    • India
    • Japan
    • South Korea
    • Malaysia
    • Philippines
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC
    • North Africa
    • South Africa
    • Rest of the Middle East & Africa

Frequently Asked Questions

What is the current size of nanomedicine market?
According to Precedence Research, the global nanomedicine market size was reached at US$ 170 billion in 2022 and is anticipated to rake US$ 493.67 billion by 2032.
What will be the CAGR of global nanomedicine market?
The global nanomedicine market growth is expanding at a CAGR of 11.30% from 2023 to 2032.
Who are the major players operating in the nanomedicine market?
The major players operating in the nanomedicine market are Sanofi SA, Abbott, Pfizer Inc., CombiMatrix Corporation, GE Healthcare, Celgene Corporation, Johnson & Johnson Services Inc., Luminex Corporation, Merck & Company Inc., and Nanosphere Inc.
Which are the driving factors of the nanomedicine market?
The factors that are driving the growth of the global nanomedicine market include numerous technological developments in nanoscale technologies for improved diagnostic techniques.
Which region will lead the global nanomedicine market?
North America region will lead the global nanomedicine market during the forecast period 2023 to 2032.

PROCEED TO BUY :

   USD 4900
   USD 3800
   USD 2100
   USD 2100
   USD 7500

ASK FOR SAMPLE

No cookie-cutter, only authentic analysis – take the 1st step to become a Precedence Research client

Get a Sample